Literature DB >> 2633046

Antibody-dependent cytotoxicity mediated by natural killer cells is enhanced by castanospermine-induced alterations of IgG glycosylation.

R J Rothman1, B Perussia, D Herlyn, L Warren.   

Abstract

Inhibitors of glycosylation and carbohydrate processing were used to probe the functional consequences of specific, differential alterations in glycosylation of monoclonal IgG secreted by hybridoma clones. Neither the absence of glycosylation nor the presence of atypical oligosaccharides significantly influenced binding of the monoclonal antibody to the cell surface antigen recognized. However, lymphocyte-mediated antibody-dependent cytotoxicity was enhanced significantly, as compared to native (unmodified) IgG-sensitized target cells, when target cells were sensitized with IgG bearing the atypical oligosaccharides induced metabolically by castanospermine, N-methyldeoxynojirimycin, deoxymannojirimycin or monesin, but not by swainsonine. The enhanced cytotoxicity was mediated by natural killer cells but not by monocytes or interferon-activated polymorphonuclear leukocytes. By contrast, antibody-dependent cytotoxicity mediated by activated polymorphonuclear leukocytes against target cells sensitized with the IgG glycosylation phenotypes induced by swainsonine and tunicamycin, but not by castanospermine, was decreased in comparison to cytotoxicity against target cells sensitized with native IgG. The enhanced lymphocyte-mediated cytotoxicity was Fc receptor-dependent. A panel of monoclonal antibodies directed against different human tumor target cells was used to demonstrate that the castanospermine-induced IgG phenotype generally enhanced antibody-dependent tumoricidal activity mediated by natural killer cells. However, differences in lymphocyte response to an alteration in IgG glycosylation were observed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2633046     DOI: 10.1016/0161-5890(89)90055-2

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  11 in total

1.  The history of IgG glycosylation and where we are now.

Authors:  Brian A Cobb
Journal:  Glycobiology       Date:  2020-03-20       Impact factor: 4.313

2.  IgG1 conformational behavior: elucidation of the N-glycosylation role via molecular dynamics.

Authors:  Simona Saporiti; Chiara Parravicini; Carlo Pergola; Uliano Guerrini; Mara Rossi; Fabio Centola; Ivano Eberini
Journal:  Biophys J       Date:  2021-10-26       Impact factor: 4.033

3.  Rapid Antibody Glycoengineering in CHO Cells Via RNA Interference and CGE-LIF N-Glycomics.

Authors:  Pavlos Kotidis; Masue Marbiah; Roberto Donini; Itzcóatl A Gómez; Ioscani Jimenez Del Val; Stuart M Haslam; Karen M Polizzi; Cleo Kontoravdi
Journal:  Methods Mol Biol       Date:  2022

4.  Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not interfere with antibody effector functions.

Authors:  M Awwad; P G Strome; S C Gilman; H R Axelrod
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

Review 5.  Emerging methods for the production of homogeneous human glycoproteins.

Authors:  Jamie R Rich; Stephen G Withers
Journal:  Nat Chem Biol       Date:  2009-04       Impact factor: 15.040

6.  Comprehensive manipulation of glycosylation profiles across development scales.

Authors:  Sven Loebrich; Elisa Clark; Kristina Ladd; Stefani Takahashi; Anna Brousseau; Seth Kitchener; Robert Herbst; Thomas Ryll
Journal:  MAbs       Date:  2018-10-22       Impact factor: 5.857

Review 7.  Glycoengineering Chinese hamster ovary cells: a short history.

Authors:  Roberto Donini; Stuart M Haslam; Cleo Kontoravdi
Journal:  Biochem Soc Trans       Date:  2021-04-30       Impact factor: 5.407

Review 8.  Fc glycans of therapeutic antibodies as critical quality attributes.

Authors:  Dietmar Reusch; Max L Tejada
Journal:  Glycobiology       Date:  2015-08-11       Impact factor: 4.313

Review 9.  Protein Glycoengineering: An Approach for Improving Protein Properties.

Authors:  Bo Ma; Xiaoyang Guan; Yaohao Li; Shiying Shang; Jing Li; Zhongping Tan
Journal:  Front Chem       Date:  2020-07-23       Impact factor: 5.221

Review 10.  Improving Immunotherapy Through Glycodesign.

Authors:  Matthew J Buettner; Sagar R Shah; Christopher T Saeui; Ryan Ariss; Kevin J Yarema
Journal:  Front Immunol       Date:  2018-11-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.